Are there specific variants or clinical signatures of chronic cGVHD that respond better to ECP therapy than others? What other second line therapies, including ibrutinib, have been evaluated and/or FDA-approved?

Are there specific variants or clinical signatures of chronic cGVHD that respond better to ECP therapy than others? What other second line therapies, including ibrutinib, have been evaluated and/or FDA-approved?

CLICK HERE FOR CME CREDIT

Are there specific variants or clinical signatures of chronic cGVHD that respond better to ECP therapy than others? What other second line therapies, including ibrutinib, have been evaluated and/or FDA-approved? 

Created by

CMEducation Resources IQ&A Extracorporeal Photopheresis Intelligence Zone | The Multi-Specialty Perspective

Presenter

Daniel Couriel, MD, MS

Daniel Couriel, MD, MS

Daniel R. Couriel, MD, MS
Professor of Internal Medicine
Director, Huntsman Cancer Institute (HCI) Blood and Marrow Transplant Program
University of Utah School of Medicine
Salt Lake City, UT